Q2 2025 Protalix Biotherapeutics Inc Earnings Call Transcript
Key Points
- Protalix BioTherapeutics Inc (PLX) experienced a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period last year, driven primarily by sales of Elfabrio to Chiesi.
- Chiesi, an international biopharmaceutical group, is a strong partner for the commercialization of Elfabrio, focusing on distribution, patient acquisition, retention, and payer reimbursement.
- Protalix anticipates Elfabrio royalties exceeding $100 million by 2030, based on a projected 15% to 20% market share of the estimated $3.2 billion Fabry total market.
- The European Medicine Agency (EMA) is reviewing a variation submission for Elfabrio to include a less frequent dosing regimen, which could enhance patient compliance.
- Protalix is progressing towards the initiation of a Phase II study for their gout product candidate, PRX-115, with promising results from a first-in-human study suggesting a long-acting effect.
- There may be quarters with no bulk orders from Chiesi due to inventory destocking, affecting revenue recognition for Protalix.
- Revenues from license and R&D services are minimal, with expectations of only potential regulatory milestone payments.
- Research and development expenses increased by 100% compared to the previous year, primarily due to preparations for the planned Phase II clinical trial of PRX-115.
- Financial expenses increased due to exchange rate costs and lower interest income, impacting net financial results.
- Protalix recorded tax expenses of approximately $0.5 million for the quarter, compared to a tax benefit in the same period last year, due to changes in US tax legislation.
Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics second-quarter 2025 financial and business results conference call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Mike Moyer, with LifeSci Advisors. You may begin your conference.
Thank you, operator, and welcome to the Protalix BioTherapeutics second-quarter 2025 financial results and business update conference call. With me today are Dror Bashan, President and CEO of Protalix; Eyal Rubin, Senior Vice President and Chief Financial Officer.
A press release announcing the financial results for the quarter and corporate updates was issued this morning and is now available on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
